Progressive and atypical neurological symptoms in refractory systemic AL amyloidosis

Kyle RA, Larson DR, Kurtin PJ et al (2019) Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin Proc 94:465–471. https://doi.org/10.1016/j.mayocp.2018.08.041 Article PubMed PubMed Central Google Scholar Perfetto F, Cappelli F, Bergesio F et al (2013) Cardiac amyloidosis: the heart of the matter. Intern Emerg Med 8:191–203 Article Google Scholar Van Gameren II, Hazenberg BPC, Bijzet J, Van Rijswijk MH (2006) Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum 54:2015–2021. https://doi.org/10.1002/art.21902 Article PubMed Google Scholar Wechalekar AD, Schonland SO, Kastritis E et al (2013) A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 121:3420–3427. https://doi.org/10.1182/blood-2012-12-473066 CAS Article PubMed Google Scholar Palladini G, Sachchithanantham S, Milani P et al (2015) A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 126:612–615. https://doi.org/10.1182/blood-2015-01-620302 CAS Article PubMed Google Scholar Vaxman I, Gertz M (2019) Recent advances in the diagnosis, risk stratification, and management of systemic light-chain amyloidosis. Acta Haematol 141:93–106 CAS Article Google Scholar Palladini G, Milani P, Foli A et al (2014) Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. Leukemia 28:2311–2316. https://doi.org/10.1038/leu.2014.227 CAS Article PubMed Google Scholar Sobol U, Stiff P (2014) Neurologic aspects of plasma cell disorders. Handbook of clinical neurology. Elsevier B.V., Amsterdam, pp 1083–1099 Google Scholar Matsuda M, Gono T, Morita H et al (2011) Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study. Eur J Neurol 18:604–610. https://doi.org/10.1111/j.1468-1331.2010.03215.x CAS Article PubMed Google Scholar Rajkumar SV, Hayman SR, Lacy MQ et al (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106:4050–4053. https://doi.org/10.1182/blood-2005-07-2817 CAS Article PubMed PubMed Central Google Scholar Rotter J, Dowlati E, Jha RT et al (2019) Primary cervical spine AL-κ amyloidoma: a case report and review of the literature. Neuropathology 39:231–239. https://doi.org/10.1111/neup.12556 CAS Article PubMed Google Scholar Sadek I, Kapoor P, Gertz MA, Kumar S (2010) An unusual neurological complication of light chain amyloidosis: images in haematology. Br J Haematol 148:816. https://doi.org/10.1111/j.1365-2141.2009.07897.x Article PubMed Google Scholar Chantry A, Kazmi M, Barrington S et al (2017) Guidelines for the use of imaging in the management of patients with myeloma. Br J Haematol 178:380–393. https://doi.org/10.1111/bjh.14827 Article PubMed Google Scholar Rahmouni A, Divine M, Mathieu D et al (1993) Detection of multiple myeloma involving the spine: efficacy of fat- suppression and contrast-enhanced MR imaging. Am J Roentgenol 160:1049–1052. https://doi.org/10.2214/ajr.160.5.8470574 CAS Article Google Scholar Glaudemans AWJM, Slart RHJA, Noordzij W et al (2013) Utility of 18F-FDG PET(/CT) in patients with systemic and localized amyloidosis. Eur J Nucl Med Mol Imaging 40:1095–1101. https://doi.org/10.1007/s00259-013-2375-1 CAS Article PubMed Google Scholar Farrell K, Stobo DB, Soutar R (2011) Cervical amyloidoma successfully treated with bortezomib and dexamethasone. J Clin Oncol 29:e512–e513. https://doi.org/10.1200/JCO.2011.34.6452 Article PubMed Google Scholar Samandouras G, Teddy PJ, Cadoux-Hudson T, Ansorge O (2006) Amyloid in neurosurgical and neurological practice. J Clin Neurosci 13:159–167 CAS Article Google Scholar Barison A, Aquaro GD, Pugliese NR et al (2015) Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging. J Intern Med 277:605–614. https://doi.org/10.1111/joim.12324 CAS Article PubMed Google Scholar Fontana M, Pica S, Reant P et al (2015) Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 132:1570–1579. https://doi.org/10.1161/CIRCULATIONAHA.115.016567 CAS Article PubMed PubMed Central Google Scholar Berg AM, Anderson JJ, Chipkin SR et al (1994) Autonomic neuropathy in AL (primary) amyloidosis and its effect on survival. Amyloid 1:39–46. https://doi.org/10.3109/13506129409148623 CAS Article Google Scholar Dispenzieri A, Dingli D, Kumar SK et al (2010) Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol 85:757–759. https://doi.org/10.1002/ajh.21822 CAS Article PubMed PubMed Central Google Scholar Download references Tuscan Regional Amyloid Center, Careggi University Hospital, Florence, Italy Federico Perfetto, Massimo Di Gioia, Marco Allinovi, Giulia Taborchi \u0026 Francesco Cappelli Department of Neurosciences, Psychology, Pharmacology and Child Health, University of Florence, Largo Brambilla 3, 50134, Florence, Italy Silvia Casagrande \u0026 Alessandro Barilaro Pathological Anatomy Unit, Careggi University Hospital, Florence, Italy Raffaella Santi Nephrology Unit, Careggi University Hospital, Florence, Italy Marco Allinovi Unit of Spine Surgery, Careggi University Hospital, Florence, Italy Stefano Romoli \u0026 Andrea Boschi Neuroradiology Unit, Careggi University Hospital, Florence, Italy Ilaria Desideri Interventional Structural Cardiology Division, Careggi University Hospital, Florence, Italy Francesco Cappelli Syncope Unit, Geriatric Intensive Care Medicine,...